ILCC 2022 Conference Coverage
Avatar

1L Single Agent Immunotherapy for mNSCLC

By ILCC 2022 Conference Coverage FEATURING Anne Chiang
By ILCC 2022 Conference Coverage FEATURING Anne Chiang
624 views
August 23, 2022
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
18:47
Total Health

Updates in the Management of NSCLC: Systemic Therapy Year in Review

Feat. W. Iams
35:40
Balazs Halmos

Year in Review: Lung Cancer

17:20
Total Health

2024 Intervention Selection & Sequencing in Early Stage NSCLC

Feat. J. Porter
08:49
David Carbone

The Use of IO Doublet in PD-L1-Negative NSCLC

13:19
IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage

Duration of Immunotherapy Beyond 2 Years for Patients With Advanced …

Feat. E. Rodriguez
14:49
Vivek Subbiah

Year in Review: Precision Medicine

07:31
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "KEYNOTE-671 Trial Key Learnings & Cli…

Feat. J. West
16:12
Total Health

2024 Updates on the Fast-Changing NSCLC Landscape

Feat. R. Osarogiagbon
23:32
2023 West Oncology Conference

2023 Updates on Neoadjuvant and Adjuvant NSCLC

Feat. M. Johnson
17:34
ecancer

Recent NSCLC Updates Including PAPILLON, CHECKMATE 77T, and KEYNOTE-…

Feat. L. Raez
11:50
GRACE

The CheckMate 816 Trial: The Success of Neoadjuvant NSCLC Therapies

Feat. J. Rotow
20:27
Yale Cancer Center

Progress in the Treatment of NSCLC

Feat. R. Herbst
08:30
Insights from 2023 ESMO Annual Meeting

PAPILLON Study - Amivantamab + Chemo vs. Chemo as 1L Treatment in EG…

Feat. N. Girard
54:26
Yale Cancer Center

Year in Review: Progress in NSCLC Treatment

Feat. R. Herbst
23:36
CHEST 2022 Coverage

Immune Checkpoint Inhibitor Pneumonitis in Lung Cancer

Feat. J. Possick
26:42
Total Health

ADAURA & KEYNOTE-671 Trials: Early Stage NSCLC Updates - 2023 AS…

Feat. J. Bauman
17:57
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "Expert Discussion on New Treatment Options…

Feat. D. Carbone, B. Stiles
08:05
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "ARC-7: Randomized Phase 2 Study of Domvan…

Feat. M. Johnson
08:15
ecancer

ESMO 2023 Summary: "Highlights From Recent NSCLC Trials"

Feat. B. Gyawali
23:29
2023 Evolution Conference

IO and Targeted Treatment for mNSCLC

Feat. M. Mooradian